vs
Side-by-side financial comparison of Spero Therapeutics, Inc. (SPRO) and SR Bancorp, Inc. (SRBK). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $8.4M, roughly 1.5× SR Bancorp, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 10.0%, a 240.7% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 6.4%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs -2.4%).
SR Bancorp Inc. is a regional bank holding company based in the United States. It offers a full range of consumer and commercial banking services including deposit products, personal loans, mortgage lending, small business financing, and commercial credit solutions, primarily serving local communities and small to mid-sized enterprises in its operating areas.
SPRO vs SRBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $12.6M | $8.4M |
| Net Profit | $31.5M | $834.0K |
| Gross Margin | — | — |
| Operating Margin | — | 13.0% |
| Net Margin | 250.7% | 10.0% |
| Revenue YoY | 24080.8% | 6.4% |
| Net Profit YoY | 250.9% | -18.3% |
| EPS (diluted) | $0.56 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.6M | $8.4M | ||
| Q3 25 | $0 | $8.2M | ||
| Q2 25 | $0 | $7.6M | ||
| Q1 25 | $12.0K | $7.7M | ||
| Q4 24 | $52.0K | $7.9M | ||
| Q3 24 | $65.0K | $8.4M | ||
| Q2 24 | $114.0K | $7.9M | ||
| Q1 24 | $140.0K | $8.8M |
| Q4 25 | $31.5M | $834.0K | ||
| Q3 25 | $-7.4M | $693.0K | ||
| Q2 25 | $-1.7M | $2.2M | ||
| Q1 25 | $-13.9M | $537.0K | ||
| Q4 24 | — | $1.0M | ||
| Q3 24 | $-17.1M | $1.4M | ||
| Q2 24 | $-17.9M | $-3.0M | ||
| Q1 24 | $-12.7M | $1.1M |
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | 11.0% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | -122758.3% | 8.1% | ||
| Q4 24 | — | 17.1% | ||
| Q3 24 | -28604.6% | 20.6% | ||
| Q2 24 | -16720.2% | -34.0% | ||
| Q1 24 | -9987.1% | 15.4% |
| Q4 25 | 250.7% | 10.0% | ||
| Q3 25 | — | 8.5% | ||
| Q2 25 | — | 29.2% | ||
| Q1 25 | -115550.0% | 7.0% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | -26380.0% | 16.3% | ||
| Q2 24 | -15668.4% | -38.2% | ||
| Q1 24 | -9049.3% | 12.1% |
| Q4 25 | $0.56 | $0.11 | ||
| Q3 25 | $-0.13 | $0.09 | ||
| Q2 25 | $-0.03 | $0.27 | ||
| Q1 25 | $-0.25 | $0.06 | ||
| Q4 24 | — | $0.12 | ||
| Q3 24 | $-0.32 | $0.16 | ||
| Q2 24 | $-0.33 | $8.14 | ||
| Q1 24 | $-0.24 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.3M | $81.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $59.0M | $188.5M |
| Total Assets | $68.9M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.3M | $81.8M | ||
| Q3 25 | $48.6M | $58.3M | ||
| Q2 25 | $31.2M | $57.8M | ||
| Q1 25 | $48.9M | $62.2M | ||
| Q4 24 | $52.9M | $53.4M | ||
| Q3 24 | $76.3M | $47.3M | ||
| Q2 24 | $63.5M | $45.9M | ||
| Q1 24 | $82.3M | $72.5M |
| Q4 25 | $59.0M | $188.5M | ||
| Q3 25 | $26.5M | $191.9M | ||
| Q2 25 | $32.8M | $193.8M | ||
| Q1 25 | $33.8M | $195.1M | ||
| Q4 24 | $46.1M | $198.1M | ||
| Q3 24 | $65.5M | $200.5M | ||
| Q2 24 | $80.5M | $199.5M | ||
| Q1 24 | $96.2M | $199.3M |
| Q4 25 | $68.9M | $1.1B | ||
| Q3 25 | $54.2M | $1.1B | ||
| Q2 25 | $62.1M | $1.1B | ||
| Q1 25 | $77.7M | $1.1B | ||
| Q4 24 | $110.5M | $1.1B | ||
| Q3 24 | $135.2M | $1.1B | ||
| Q2 24 | $149.9M | $1.0B | ||
| Q1 24 | $167.7M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.4M | $3.6M |
| Free Cash FlowOCF − Capex | — | $3.1M |
| FCF MarginFCF / Revenue | — | 37.0% |
| Capex IntensityCapex / Revenue | — | 5.9% |
| Cash ConversionOCF / Net Profit | -0.26× | 4.31× |
| TTM Free Cash FlowTrailing 4 quarters | — | $11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.4M | $3.6M | ||
| Q3 25 | $17.4M | $1.2M | ||
| Q2 25 | $-17.7M | $4.7M | ||
| Q1 25 | $-4.0M | $2.6M | ||
| Q4 24 | $-23.4M | $-1.4M | ||
| Q3 24 | $12.8M | $1.8M | ||
| Q2 24 | $-18.7M | $-1.7M | ||
| Q1 24 | $5.9M | $-3.9M |
| Q4 25 | — | $3.1M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $4.2M | ||
| Q1 25 | — | $2.5M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $-2.8M | ||
| Q1 24 | — | $-4.0M |
| Q4 25 | — | 37.0% | ||
| Q3 25 | — | 14.0% | ||
| Q2 25 | — | 55.9% | ||
| Q1 25 | — | 32.3% | ||
| Q4 24 | — | -19.5% | ||
| Q3 24 | — | 20.3% | ||
| Q2 24 | — | -35.8% | ||
| Q1 24 | — | -45.2% |
| Q4 25 | — | 5.9% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 5.7% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 13.9% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | -0.26× | 4.31× | ||
| Q3 25 | — | 1.76× | ||
| Q2 25 | — | 2.11× | ||
| Q1 25 | — | 4.79× | ||
| Q4 24 | — | -1.40× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -3.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
